[Attempt at using chemoluminescence in modern diagnosis and monitoring of therapy in prostatic cancer].
The nature of chemoluminescence (Chl) is based on the measurement of plasma luminescence intensity, using a photoelectric system. In a group of 42 patients with prostatic cancer (PC), in 29 cases (69.0%) an increase of Chl was found while in 20 blood donors (control group) the Chl result was negative. Out of 29 patients with PC, Chl was studied in 20 cases for 12 months. These were patients after orchidectomy treated with flutamide. Chl demonstrated in them a decrease of luminescence intensity which correlated with a decrease of the level of prostatic markers (particularly PSA). These results may suggest that Chl may be a useful method in early diagnosis and probably may serve for trials of PC therapy monitoring. Further studies are necessary however, especially in order to explain the divergences in Chl measurements observed in individual cases, and to confirm the value of the method which is easy to perform at low expenses.